Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurotech InternationalASX:NTI -11.11% 14-Day RSI is 53.73 as of Jul. 19, 2026. The stock has 1 warning sign investors should review. Among 1,425 Biotechnology companies, Neurotech International ranks worse than 76.98% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The industry rank for Neurotech International's 14-Day RSI or its related term are showing as below:
ASX:NTI's 14-Day RSI is ranked worse than 76.98% of 1425
companies
in the Biotechnology industry
Industry Median: 45.58
vs ASX:NTI: 53.73
Neurotech International (ASX:NTI) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Neurotech International 14-Day RSI Related Terms
ASX:NTI vs VRTX, REGN, ALNY: 14-Day RSI Comparison
For the Biotechnology subindustry, Neurotech International's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurotech International 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neurotech International's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Neurotech International's 14-Day RSI falls into.
Neurotech International (ASX:NTI) 14-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurotech International (ASX:NTI) has a 14-Day RSI of 53.73 as of Jul. 19, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Neurotech International and its competitors. According to the industry distribution chart, Neurotech International ranks #1097 out of 1425 companies in the Biotechnology industry, placing it in the top 77%.
Is Neurotech International's 14-Day RSI too high?
Neurotech International's current 14-Day RSI is 53.73. The Biotechnology industry median 14-Day RSI is 45.58. Neurotech International's value of 53.73 is 17.9% above this industry median. Based on the distribution chart, Neurotech International ranks #1097 out of 1425 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neurotech International's 14-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neurotech International ranks #1097 out of 1425 companies for 14-Day RSI. This places Neurotech International in the lower half of its industry. The industry median 14-Day RSI is 45.58. Neurotech International's value of 53.73 is 17.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 45.58, based on 1,425 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurotech International's current 14-Day RSI of 53.73 is 17.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Neurotech International and its competitors. For the Biotechnology industry, the median 14-Day RSI is 45.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurotech International's current 14-Day RSI is 53.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurotech International stock overvalued right now?
Neurotech International (ASX:NTI) has a current 14-Day RSI of 53.73. The current 14-Day RSI is 53.73 and 17.9% above the Biotechnology industry median of 45.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Neurotech International (ASX:NTI), the current 14-Day RSI is 53.73 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NTI has been successfully added to your 
